AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00268450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Before surgery: given as a 1000mg/m2 IV over 30 minutes on days 1 and 8 of a 21 day cycle for 4 cycles
Study NCT00268450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: After surgery: given as a 175 mg/m2 dose ver 3 hours every 21 days for 3 cycles
Study NCT00268450 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cysectomy
Study NCT01373359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 400 µg sublingual misoprostol
Study NCT01373359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 10 IU IM
Study NCT01293201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAHIST
Description: STAHIST dosed one tablet, BID
Study NCT01293201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical in appearance to IMP, dosed one tablet BID
Study NCT01062776 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dehydration
Description: Furosemide 5 mg is given intravenously over 2 hours until approximately 2 liters of body fluid is lost.
Study NCT01062776 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No dehydration is induced
Study NCT05793580 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Vibrant Soundbridge active middle ear implant
Description: active middle ear implant
Study NCT01962376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin;Capecitabine
Description: A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.
Study NCT01962376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin;Capecitabine
Description: A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.
Study NCT01962376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin;Capecitabine;Bevacizumab
Description: A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.
Study NCT01962376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin;Capecitabine;Bevacizumab
Description: A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.
Study NCT01860313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text and Video-based education
Description: This group received the material that composed the web-based education environment without any kind of interactivity. This material was composed by some videos about children mental health and a support text.
Study NCT00042939 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Patients received cetuximab intravenous infusions, via infusion pump or syringe pump, once a week for 6 weeks.
Study NCT00042939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Docetaxel was administered intravenously over 60 minutes at a dose of 35 mg/m² once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest. Docetaxel was diluted in 100-150 ml of infusion solution.
Study NCT00042939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel was administered intravenously over 60 minutes at a dose of 35 mg/m² once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest. Docetaxel was diluted in 100-150 ml of infusion solution.
Study NCT00042939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan hydrochloride
Description: After the completion of the docetaxel infusion, irinotecan was administered intravenously over 30 minutes at a dose of 50 mg/m² once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest.
Study NCT00042939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: After the completion of the docetaxel infusion, irinotecan was administered intravenously over 30 minutes at a dose of 50 mg/m² once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest.
Study NCT02594267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate Injection
Description: Drug: Folotyn (Pralatrexate Injection)~CHOP : Cyclophosphamide, Doxorubicin, Vincristine, \& Prednisone
Study NCT02082639 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix™
Description: 2 doses intramuscularly in the deltoid muscle of the non-dominant arm
Study NCT02082639 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: 2 doses intramuscularly in the deltoid muscle of the dominant arm
Study NCT04217798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Subjects will receive niraparib combined with oral etoposide (on day 1-20, every 30 days). After 6-8 cycles, oral etoposide will be terminated. Niraparib will be still given to subjects until disease progression, intolerable toxicity or withdrawal of informed consent.
Study NCT02699398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Domiciliary VR-based motor rehabilitation
Description: 3 weeks, 1 to 3 sessions a day, 20min per sessions, of physical therapy using a VR gaming system.
Study NCT02699398 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Domiciliary occupational therapy for motor rehabilitation
Description: 3 weeks, 1 to 3 sessions a day, 20min per sessions, of physical therapy using a VR gaming system.
Study NCT02761668 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ParS+Ortho 4W
Description: Orthodontics 4 weeks post surgical
Study NCT01709045 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: Multi-sequence MR protocol
Study NCT01709045 — intervention group
Intervention type: RADIATION
Intervention: Dual-Energy Computed Tomography (DECT)
Study NCT02761668 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ParS+Ortho 6M
Description: Orthodontics 6 months post surgical
Study NCT00765180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRE vs. NBI
Description: TRE NBI
Study NCT01709045 — intervention group
Intervention type: OTHER
Intervention: Ultrasound
Study NCT01709045 — intervention group
Intervention type: OTHER
Intervention: Transcranial doppler
Study NCT04097314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zibotentan
Description: 10mg OD Zibotentan
Study NCT04097314 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo
Study NCT00472082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efalizumab
Description: Administration of a test dose of efalizumab 0.7mg/kg will be administered at enrollment. Weekly subcutaneous injections of efalizumab 1mg/kg will begin with study visit 2 and continue for 1 year for this pilot study.
Study NCT04238117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser acupuncture treatment
Description: Laser acupuncture therapy (LAT) is a noninvasive technique that involves stimulation of traditional acupoints with low intensity, non thermal laser irradiation.
Study NCT03010046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX005
Description: Single ascending dose intravenous infusion
Study NCT03010046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIg
Description: IVIg infusion in Cohorts 4b and 5b only. Randomized to ANX005 followed by IVIg or placebo followed by IVIg.
Study NCT03010046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 0.9% saline intravenous infusion
Study NCT04131465 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Home HIV self-testing
Description: Offer of 3 OraQuick HIV self-test kits
Study NCT00765180 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRE vs. NBI
Description: TRE NBI
Study NCT03054649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HARMONI® Modular Intraocular Lens System
Description: Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag
Study NCT00865761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 3 mg Extended Release Tablets, single dose
Description: A: Experimental Subjects received Alpharma formulated products under fasting conditions
Study NCT00865761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XANAX XR® 3 mg tablets, single dose
Description: B: Active comparator Subjects received Pharmacia \& Upjohn Company formulated products under fasting conditions
Study NCT04565574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7090
Description: Oral tablet.
Study NCT04565574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Description: Rabeprazole 20 mg (2 tablets, each of 10 mg) oral tablet.
Study NCT04565574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg
Description: Rifampin 600 mg (4 capsules, each of 150 mg) oral capsule.
Study NCT03668808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: Subjects will use Insulin Degludec (Tresiba) with TRESIBA® FLEXTOUCH® pens as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.
Study NCT03668808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Subjects will use Insulin Glargine (Lantus) with LANTUS® SOLOSTAR® INSULIN PEN as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.
Study NCT03668808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRESIBA® FLEXTOUCH®
Description: Subjects will use Tresiba FlexTouch pens when using Tresiba as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.
Study NCT03668808 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LANTUS® SOLOSTAR® INSULIN PEN
Description: Subjects will use Lantus SoloStar insulin pens when using Lantus as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.
Study NCT01808547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISV-303
Description: 0.075% bromfenac in DuraSite dosed BID
Study NCT01808547 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DuraSite Vehicle
Description: DuraSite vehicle dosed BID
Study NCT02277535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feedback/Reminder email.
Study NCT02271932 — intervention group
Intervention type: OTHER
Intervention: Non-operative
Description: Patients will receive only antibiotics and will not undergo appendectomy unless they do not improve or their appendicitis recurs
Study NCT03881293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine 2% gel
Description: Transurethral instillation of 5 ml lidocaine 2% gel
Study NCT03881293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: water soluble lubricant
Description: Transurethral instillation of 5 ml water soluble lubricant
Study NCT03087500 — intervention group
Intervention type: OTHER
Intervention: There is no other intervention, only clinical treatment.
Description: There is no other intervention, only clinical treatment.
Study NCT03362814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravidasvir
Description: Ravidasvir 200mg tablet administered orally once daily
Study NCT03362814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danoprevir
Description: Danoprevir 100mg tablet administered orally twice daily
Study NCT03362814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 100mg tablet administered orally twice daily
Study NCT03362814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin 100 MG
Description: Ribavirin tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations(\<75kg = 1000mg and ≥75kg = 1200mg)
Study NCT03362814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ravidasvir Placebo
Description: Ravidasvir Placebo tablet administered orally once daily
Study NCT03054649 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative optic exchange
Description: Removal of one optic and replacement with another during cataract surgery for the purpose of improving refractive outcomes
Study NCT03852667 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Neuroscience Education
Description: The PNE intervention consisted of 2 sessions of 30 minutes. In the first session, the main goal is to explain the patient why pain is important and why people can't live without it. Besides it is explained why objective findings such as x-rays, MRI, CT scans, etc. often lack significant findings despite the pain that the patient experiences. This first session of pain education might help the patient understand that pain is necessarily a result from tissue damage. Furthermore, the session explains the right approach to conquer pain and to avoid going down in this vicious circle of low back pain. The second session of PNE, is a revision of the first session, continuing on what was unclear from the first session.
Study NCT03852667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: The PNE intervention consisted of 2 sessions of 30 minutes. In the first session, the main goal is to explain the patient why pain is important and why people can't live without it. Besides it is explained why objective findings such as x-rays, MRI, CT scans, etc. often lack significant findings despite the pain that the patient experiences. This first session of pain education might help the patient understand that pain is necessarily a result from tissue damage. Furthermore, the session explains the right approach to conquer pain and to avoid going down in this vicious circle of low back pain. The second session of PNE, is a revision of the first session, continuing on what was unclear from the first session.
Study NCT03852667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: The exercise therapy varies form analytical exercises in the first sessions, to functional and sports related exercises near the following sessions. The first session focuses on the lumbar neuromuscular control of the patients: first a voluntary contraction of the Transversus Abdominis muscle, the Multifidus muscle and the pelvic floor muscles is learned. When the subject is able to maintain the combined contraction for 10 times, the exercises evolve to more complicated tasks. In the final stage, more functional and sport specific tasks will be exercised.
Study NCT00275067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Description: Arsenic trioxide administered intravenously at a dose of 0.20mg/kg Daily x 5 week then twice per week
Study NCT00275067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Temozolomide administered orally once per day 1 hour prior to radiation therapy at a dose of 75 mg/m2 x 42 days; at a dose of 200mg/m2 for 5 days every cycle (1 cycle = 28 days) after radiation therapy
Study NCT00275067 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: All patients will receive 5940-6120 cGy of radiation therapy as 28-33 treatments/fractions (180-200 cGy/treatment) depending on whether they receive standard 3-D conformal radiation therapy or intensity modulated radiation therapy.
Study NCT04131465 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Home HIV rapid testing
Description: Offer of HIV rapid testing with Alere Determine HIV-1/2
Study NCT04131465 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Home HIV self-testing and rapid testing
Description: Offer of 3 OraQuick HIV self-test kits and HIV rapid testing with Alere Determine HIV-1/2
Study NCT03100604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desflurane,
Description: Patients were divided into two groups according to inhalation agent administered for the surgery; Sevofluran, Group S (n=25) and Desfluran, Group D (N=25).
Study NCT03100604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: For a drug, use generic name if established. Use the same name as in the associated Arm/Group Description(s).
Study NCT02923856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The results of clarithromycin susceptibility test of H. pylori isolates
Description: According to the results of antibiotic susceptible testing, patients who were resistant to clarithromycin were belonged into clarithromycin resistance group.Patients who were sensitive to clarithromycin were belonged into the 7days/10days/14days treatment groups.
Study NCT04058847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Your Heart Forecast
Description: 1 year follow up with Your Heart Forecast and a follow-up email every 2 weeks.
Study NCT02923856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer generated random number, randomly assigned into groups
Description: The patients with clarithromycin sensitive. Computer generated random number,randomly assigned into 7days/10days/14days treatment groups.
Study NCT02923856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The result of 13C-urea breath test of patient in 7days/10days/14days treatment groups
Description: The intervention focused on the results from the result of 13C-urea breath test at 8 weeks after treatment in patients. All patients were taking 75mg 13C-urea and analysis with a modified isotope ratio mass spectrometer to determine the 13CO2 content.The successful treatment groups were patients with negative in 13C-urea breath tests.The failed treatment of H. pylori groups were patients with positive in 13C-urea breath tests after the standardized triple therapy treatment.
Study NCT02022228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin
Description: 0.2 mg triptorelin, ih
Study NCT02022228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Description: 1000 IU hCG, im
Study NCT02022228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Description: 500IU hCG, im
Study NCT01388946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.75
Study NCT01388946 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study NCT03799198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Management Program (WMP)
Description: As part of usual care, participants will: 1) Discuss and choose one of three diet options: protein-sparing modified fast, Mediterranean, or meal replacement. 2) Be referred to a nutritionist appointment. 3) Initiate a series of twelve monthly study visits in the context of shared medical appointments (SMAs) covering nutrition, physical activity, appetite control, sleep issues, and anxiety/depression/stress. 4) Be referred to an exercise physiologist for a personalized physical activity program. 5) If assessed relevant by the study clinician, be referred to a mental health specialist and/or sleep clinic.
Study NCT03799198 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight Management Program (WMP)
Description: As part of usual care, participants will: 1) Discuss and choose one of three diet options: protein-sparing modified fast, Mediterranean, or meal replacement. 2) Be referred to a nutritionist appointment. 3) Initiate a series of twelve monthly study visits in the context of shared medical appointments (SMAs) covering nutrition, physical activity, appetite control, sleep issues, and anxiety/depression/stress. 4) Be referred to an exercise physiologist for a personalized physical activity program. 5) If assessed relevant by the study clinician, be referred to a mental health specialist and/or sleep clinic.
Study NCT03799198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medication for chronic weight management (Rx)
Description: Following listed 5 drugs will be administered as prescribed by the study doctor:~1) Orlistat (Xenical® pills, per os \[p.o.; by mouth\]). 2) Lorcaserin or lorcaserin extended-release (Belviq®/Belviq XR® pills, p.o.). 3) Phentermine/topiramate extended-release (Qsymia® pills, p.o.). 4) Naltrexone/bupropion extended-release (Contrave® pills, p.o.). 5) Liraglutide 3.0 mg (Saxenda® injections, subcutaneously \[under the skin\]).
Study NCT03344029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SP Shz TIV
Description: 0.5 mL, intramuscular into the deltoid muscle, single injection on Day 0
Study NCT03344029 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hualan TIV
Description: 0.5 mL, intramuscular into the deltoid muscle, single injection on Day 0
Study NCT03707106 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT smoking cessation
Description: an established protocol for smoking cessation based on cognitive behavioral therapy
Study NCT03707106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT smoking cessation
Description: an established protocol for smoking cessation based on cognitive behavioral therapy
Study NCT03707106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual reality based cue exposure
Description: smoking cue exposure in virtual reality